Copyright
©The Author(s) 2023.
World J Clin Cases. Jul 26, 2023; 11(21): 5083-5096
Published online Jul 26, 2023. doi: 10.12998/wjcc.v11.i21.5083
Published online Jul 26, 2023. doi: 10.12998/wjcc.v11.i21.5083
Variable | Placebo group | hUC-MSC group | Z | P value |
n = 10 | n = 24 | |||
Routine blood | ||||
WBC | 6.48 (5.71, 8.17) | 6.87 (5.52, 8.13) | -0.227 | 0.821 |
PLT | 232.0 (199.5, 253.8) | 214.0 (163.0, 258.3) | -0.718 | 0.473 |
RBC | 5.15 (4.58, 5.46) | 4.94 (4.79, 5.45) | -0.076 | 0.94 |
NEU | 3.80 (2.95, 4.89) | 4.20 (2.90, 5.15) | -0.189 | 0.850 |
L | 2.21 (1.69, 2.44) | 2.23 (1.96, 2.61) | -0.454 | 0.65 |
MONO | 0.45 (0.34, 0.53) | 0.36 (0.31, 0.44) | -1.192 | 0.233 |
NLR | 1.89 (1.41, 2.36) | 1.64 (1.43, 2.13) | -0.227 | 0.821 |
Liver function | ||||
ALT | 21.00 (18.00, 31.25) | 25.50 (16.50, 48.25) | -0.606 | 0.545 |
AST | 20.50 (17.00, 23.00) | 21.50 (18.00, 31.75) | -0.872 | 0.383 |
γ-GT | 27.00 (20.75, 31.00) | 34.50 (23.75, 52.00) | -1.703 | 0.089 |
TP | 73.70 (68.88, 76.93) | 71.70 (68.13, 76.78) | -0.529 | 0.597 |
GLB | 29.25 (24.63, 30.98) | 25.75 (23.93, 28.33) | -1.966 | 0.049 |
Renal function | ||||
Urea | 6.51 (4.68, 7.23) | 5.87 (5.38, 6.61) | -0.227 | 0.821 |
Cr | 65.00 (58.00, 73.00) | 67.00 (56.25, 81.00) | -0.227 | 0.82 |
eGFR | 106.59 (97.44, 111.71) | 104.52 (84.42, 111.99) | -0.454 | 0.65 |
Blood fat | ||||
TC | 4.61 (4.06, 5.38) | 3.95 (3.55, 5.40) | -1.247 | 0.212 |
TG | 1.67 (1.20, 3.04) | 1.87 (1.13, 2.79) | -0.094 | 0.925 |
LDL-C | 2.91 (2.53, 3.29) | 2.48 (2.12, 3.72) | -1.077 | 0.281 |
HDL-C | 1.14 (0.91, 1.33) | 1.12 (0.88, 1.46) | -0.019 | 0.985 |
Coagulation function | ||||
PT | 12.25 (12.00, 12.78) | 12.15 (12.00, 12.60) | -0.494 | 0.621 |
APTT | 34.05 (32.68, 37.60) | 34.10 (32.58, 35.45) | -0.284 | 0.777 |
TT | 17.95 (17.45, 19.00) | 18.00 (17.65, 18.90) | -0.265 | 0.791 |
FIB | 2.95 (2.61, 3.53) | 3.07 (2.29, 3.22) | -0.302 | 0.762 |
DD | 0.22 (0.22, 0.26) | 0.22 (0.22, 0.30) | -0.36 | 0.719 |
Infection screening | ||||
HBsAg | 0.00 (0.00, 0.00) | 0.00 (0.00, 20.31) | -1.081 | 0.28 |
HCV-Ab | 0.05 (0.04, 0.06) | 0.09 (0.04, 0.14) | -1.679 | 0.093 |
HIV-Ag/Ab | 0.07 (0.06, 0.08) | 0.06 (0.05, 0.08) | -0.731 | 0.465 |
TP-Ab | 0.04 (0.02, 0.06) | 0.04 (0.04, 0.05) | -0.776 | 0.438 |
Tumor marker | ||||
AFP | 2.80 (2.20, 3.85) | 1.95 (1.65, 3.10) | -1.494 | 0.135 |
CEA | 1.85 (1.40, 3.50) | 2.15 (1.58, 3.08) | -0.416 | 0.677 |
CA199 | 8.45 (5.20, 17.33) | 5.55 (3.35, 15.90) | -0.643 | 0.52 |
- Citation: Lian XF, Lu DH, Liu HL, Liu YJ, Yang Y, Lin Y, Xie F, Huang CH, Wu HM, Long AM, Hui CJ, Shi Y, Chen Y, Gao YF, Zhang F. Safety evaluation of human umbilical cord-mesenchymal stem cells in type 2 diabetes mellitus treatment: A phase 2 clinical trial. World J Clin Cases 2023; 11(21): 5083-5096
- URL: https://www.wjgnet.com/2307-8960/full/v11/i21/5083.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i21.5083